
Society of Surgical Oncology Highlights Roswell Park Experts at 2025 Annual Meeting
Key Takeaways
- Dr. Moshim Kukar will discuss emerging biomarkers in gastroesophageal junction cancers and guide residents on SSO fellowships.
- Dr. Gary Mann will moderate a debate on the extent of surgery in thyroid cancer care, focusing on management challenges.
Roswell Park Comprehensive Cancer Center surgeons will share their expertise during the 2025 annual meeting of the Society of Surgical Oncology.
Cancer surgery leaders from Roswell Park Comprehensive Cancer Center will share their expertise with other cancer surgeons from around the world during the 2025 annual meeting of the Society of Surgical Oncology at the Tampa Convention Center in Tampa, Florida, March 27-29.
He will chair Session 010,
Dr Kukar will also address general surgery residents who want to pursue SSO fellowships, during Session 052,
Dr Mann Heads Discussion of Thyroid Cancer Care
Dr Jehan Honored for Top-Rated Poster and Video
- Dr Jehan will present his SSO Top-Rated Poster, P224, Easel 6 — “
Mediastinalization of the Gastric Conduit by Pleural Closure in Robotic Ivor Lewis Esophagectomy: Short-Term Quality of Life Assessment ,” Thursday, March 27, from 10-10:20 a.m. in the HUB Poster Park. - He will present his SSO Top-Rated Video, 128 — “
Pleural Flap Closure to Mediastinalize the Gastric Conduit in Robotic Ivor Lewis Esophagectomy: A Novel Technique ,” Saturday, March 29, from 10:32-10:38 a.m. in Ballroom A.
Additional Research Abstracts
The work of several Roswell Park fellows will be featured as e-posters:
Drew Erali, MD, MPH , Fellow in Surgical Oncology — P411, “Outcomes of Clinically Detected Stage II Melanoma Through Individualized Neoadjuvant (PRADO) Approach at a Single Institution.”Faisal Jehan, MD, FICS , Fellow in Surgical Oncology — P27, “The Role of Neutrophil in Breast Tumor Microenvironment and Association with Response to Neoadjuvant Therapy”Aeryn Kangas-Dick , MD, Fellow in Surgical Oncology — P367, “Intratumoral Lymphangiogenesis Does Not Correlate with Outcomes in Hepatocellular Carcinoma”Olivia Martin, MD, MS , Fellow in Surgical Oncology — P30, “Tumor Hypoxia Is Associated with Markers of Increased Tumor Aggression and Response to Immunotherapy in ER+/HER2- Breast Cancer Patients”Sarah McIntyre, MD , Fellow in Surgical Oncology — P6, “Clinical Relevance of Sphingosine 1-Phosphate Receptor 4 (S1PR4) in Breast Cancer Using Bulk and Single-Cell Transcriptome Analysis”Elizabeth Olecki, MD, MScR , Fellow in Surgical Oncology — P352, “Degree of Dedifferentiation of Hepatocellular Carcinoma Is Not Associated with Decreased Expression of Sphingosine 1-Phosphate Receptor 2”- Masanori Oshi, MD, Postdoctoral Fellow in Breast Surgery — P1, “Activated Hippo Pathway Is Associated with. Worse Response to Trastuzumab and Survival in HER2-Positive Breast Cancer”
Colin Rog, MD , Fellow in Surgical Oncology — P438, “The Atypical Presentation and Delayed Timing of Anastomotic Leak in Patients Who Undergo Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy”
Talk to the Experts in Continuing the Conversation Sessions
This year’s SSO annual meeting includes Continuing the Conversation get-togethers that will give participants a chance to ask questions and share information with experts in an informal setting.
- Dr Kukar will be featured in
Continuing the Conversation: Meet the GI Experts , Thursday, March 27, from 10-10:20 a.m. EDT in the Upper GI/HPB/Colorectal HUB Zone. - Dr Mann will be featured in
Continuing the Conversation: Surgical Oncologists for Sustainability: What Is SSO Doing About Sustainability? , Thursday, March 27, from 10-10:20 a.m. EDT in the Pan-Tumor HUB Zone. Zachary Stiles, DO, MS , Assistant Professor of Oncology in the Department of Surgical Oncology, will be featured inContinuing the Conversation: Meet the Junior Faculty , Thursday, March 27, from 10-10:20 a.m. EDT in the Immuno-Oncology HUB Zone.
###
From the world’s first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide. Driven to eliminate cancer’s grip on humanity, the Roswell Park team of 4,000 makes compassionate, patient-centered cancer care and services accessible across New York State and beyond. Founded in 1898, Roswell Park was among the first three cancer centers nationwide to become a National Cancer Institute-designated comprehensive cancer center and is the only one to hold this designation in Upstate New York. To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit



































